Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2– Advanced or Metastatic Breast Cancer: A US Payer Perspective

Introduction: This study evaluated the cost-effectiveness of abemaciclib plus fulvestrant (ABE + FUL) vs. palbociclib plus fulvestrant (PAL + FUL), ribociclib plus fulvestrant (RIB + FUL) and fulvestrant monotherapy (FUL) as second-line treatment for hormone receptor-positive and human epidermal gro...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Front Med (Lausanne)
Autori principali: Wang, Yingcheng, Rui, Mingjun, Guan, Xin, Cao, Yingdan, Chen, Pingyu
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2021
Soggetti:
Medicine
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8206485/
https://ncbi.nlm.nih.gov/pubmed/34150798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2021.658747
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi